JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.02556-06v1
45/5/1611    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fosheim, G. E.
Right arrow Articles by Limbago, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fosheim, G. E.
Right arrow Articles by Limbago, B. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2007, p. 1611-1613, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.02556-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evaluation of the AdvanDx VRE EVIGENE Assay for Detection of vanA in Vancomycin-Resistant Staphylococcus aureus{triangledown}

G. E. Fosheim, R. B. Carey, and B. M. Limbago*

Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., MS C-16, Atlanta, Georgia 30333

Received 20 December 2006/ Returned for modification 13 February 2007/ Accepted 22 February 2007

AdvanDx VRE EVIGENE, a commercial vanA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated for the detection of vanA in Staphylococcus aureus. Performance was assessed using S. aureus, VRE, and vancomycin-intermediate and -susceptible isolates. The assay demonstrated 100% sensitivity and specificity when analyzed visually and by optical density.

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, MS C16, 1600 Clifton Rd., Atlanta, GA 30333. Phone: (404) 639-2162. Fax: (404) 639-3822. E-mail: BLimbago{at}cdc.gov

{triangledown} Published ahead of print on 7 March 2007.

Journal of Clinical Microbiology, May 2007, p. 1611-1613, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.02556-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.